edaravone and riluzole
edaravone has been researched along with riluzole in 22 studies
Research
Studies (22)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 14 (63.64) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Kiernan, MC; Noto, Y; Shibuya, K; Vucic, S | 1 |
| Scott, A | 1 |
| Rothstein, JD | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Jaiswal, MK | 1 |
| Schultz, J | 1 |
| Gendron, TF; Oskarsson, B; Staff, NP | 1 |
| Barp, A; Gerardi, F; Lizio, A; Lunetta, C; Sansone, VA | 1 |
| Chen, JJ | 1 |
| Eslahchi, C; Ghassempour, A; Kiaei, M; Sadr, AS | 1 |
| Chen, S; Gao, Y; Le, W; Meng, H; Ni, Y; Shen, D; Shi, H; Xu, X; Zhou, Q | 1 |
| Başak, AN; Ciftci, H; DeMirci, H; Fujita, M; Ocak, F; Otsuka, M; Sever, B; Sever, H; Tateishi, H; Tateishi, T; Yulug, B | 1 |
| Gautam, M; Genç, B; Goshu, GM; Günay, A; Hande Ozdinler, P; Helmold, BR; Koçak, N; Silverman, RB | 1 |
| Bassani, D; Federico, S; Moro, S; Pavan, M; Spalluto, G; Sturlese, M | 1 |
| Beland, B; Chhibber, S; Frost, GS; Hodgkinson, V; Jewett, G; Khayambashi, S; Korngut, L; Lee, A | 1 |
| Berry, JD; De Marchi, F; Fang, T; Johnson, SA; Neel, D; Paganoni, S; Van Weehaeghe, D | 1 |
| Borges, F; Chavarria, D; Oliveira, PJ; Silva, C; Silva, FSG; Soares, P | 1 |
| Carreira, RB; Costa, SL; da Silva, VDA; de Oliveira, JVR; de Oliveira, LMG; do Nascimento, RP; Dos Santos Souza, C; Trias, E | 1 |
| Ogino, M | 1 |
| Lynch, K | 1 |
| Aksinenko, AY; Bachurin, SO; Dubrovskaya, ES; Epishina, TA; Fisenko, VP; Goreva, TV; Grigoriev, VV; Lapshina, MA; Makhaeva, GF; Maleev, GV; Shevtsova, EF; Steinberg, DA; Ustyugov, AA; Veselov, IM; Vinogradova, DV; Zamoyski, VL | 1 |
Reviews
12 review(s) available for edaravone and riluzole
| Article | Year |
|---|---|
Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Edaravone; Humans; Motor Neurons; Neuroprotective Agents; Riluzole | 2016 |
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Topics: Administration, Intravenous; Administration, Oral; Amyotrophic Lateral Sclerosis; Brain; Edaravone; Humans; Neuroprotective Agents; Riluzole | 2018 |
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Design; Edaravone; Humans; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species; Riluzole | 2019 |
Disease-modifying treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Neuroprotective Agents; Quality of Life; Riluzole | 2018 |
Amyotrophic Lateral Sclerosis: An Update for 2018.
Topics: Amyotrophic Lateral Sclerosis; C9orf72 Protein; Diagnosis, Differential; Edaravone; Female; Humans; Male; Mesenchymal Stem Cell Transplantation; Neuroprotective Agents; Riluzole | 2018 |
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Drug Development; Drug Discovery; Edaravone; Humans; Neuroprotective Agents; Oxidative Stress; Riluzole | 2020 |
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Management; Disease Progression; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Riluzole; Stem Cell Transplantation | 2021 |
Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Combined Modality Therapy; Deep Brain Stimulation; Drug Discovery; Edaravone; Humans; Induced Pluripotent Stem Cells; Riluzole | 2022 |
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Motor Neurons; Receptors, G-Protein-Coupled; Riluzole | 2022 |
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Topics: Amyotrophic Lateral Sclerosis; Biological Products; Clinical Trials as Topic; Disease Progression; Edaravone; Humans; Neuroprotective Agents; Riluzole | 2022 |
Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
Topics: Amyotrophic Lateral Sclerosis; Drug Discovery; Edaravone; Humans; Oxidative Stress; Riluzole | 2023 |
Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Glutamic Acid; Humans; Phytochemicals; Riluzole | 2023 |
Other Studies
10 other study(ies) available for edaravone and riluzole
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Edaravone: A new drug approved for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Drug Approval; Edaravone; Excitatory Amino Acid Antagonists; Humans; Riluzole | 2017 |
Overview of current and emerging therapies for amytrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Antibodies, Monoclonal, Humanized; Benzamides; Edaravone; Humans; Mesenchymal Stem Cells; Oligonucleotides; Piperidines; Pyridines; Riluzole; Thiazoles | 2020 |
In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Computer Simulation; Edaravone; Humans; Molecular Docking Simulation; Mutant Proteins; Mutation; Neuroprotective Agents; Profilins; Protein Conformation; Riluzole | 2021 |
NU-9 improves health of hSOD1
Topics: Amyotrophic Lateral Sclerosis; Animals; Edaravone; Humans; Mice; Motor Neurons; Riluzole; Superoxide Dismutase | 2022 |
Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Edaravone; Eligibility Determination; Humans; Retrospective Studies; Riluzole | 2022 |
[Drugs for Amyotrophic Lateral Sclerosis].
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Japan; Neuroprotective Agents; Riluzole | 2023 |
Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life.
Topics: Amyotrophic Lateral Sclerosis; Edaravone; Humans; Quality of Life; Riluzole | 2023 |
New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
Topics: Adamantane; Amantadine; Amyotrophic Lateral Sclerosis; Edaravone; Humans; Neuroprotective Agents; Riluzole | 2023 |